Navigation Links
Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development

IRVINE, Calif., Sept. 21 /PRNewswire/ -- Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009. The $1.8 million grant will fund efforts to further test and validate novel candidate antigens discovered during the Company's successful STTR Phase I program. ADi intends to develop the novel antigens as core protective components in a vaccine against Chlamydia. ADi will collaborate with investigators in the Department of Pathology & Laboratory Medicine of School of Medicine at the University of California, Irvine (UCI).

"ADi's high throughput proteomics technology is a powerful platform to translate readily available genomic information into the development of next generation diagnostics, therapeutics and vaccines," said Dr. Xiaowu Liang, CEO of ADi. "Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen. An efficacious vaccine against Chlamydia will have a tremendous health and economic impact throughout the world. We are pleased to collaborate with the leading Chlamydia researcher at UCI in applying our proven platform technology to address this critical public health concern. We are also thankful and appreciative of continued support of the US Government and NIAID on this important endeavor."

"ADi's high throughput proteomics approach has allowed us, for the first time, to successfully scan the entire proteome of Chlamydia trachomatis," added Dr. Luis de la Maza, the Principal Investigator on the STTR grant. "Our goal for this phase of the project is to identify a small subset of recombinant chlamydial antigens that induce strong protection against infection challenge. These antigens will be ideal candidates to develop a novel Chlamydia vaccine."

The two year, $1.8 million, Phase II STTR grant supplements a previously awarded Phase I STTR to ADi in 2007.

About Antigen Discovery, Inc.

Antigen Discovery, Inc. (formerly ImmPORT Therapeutics, Inc.) is a privately held biotech company with innovative technologies that offer unprecedented advantages for the rapid development of vaccines, therapeutics, and diagnostic products. The Company's high throughput proteome microarray chip fabrication and screening platform provides an order of magnitude of improvement over current antigen and biomarker discovery technologies. The Company is also working on applying their platform to the identification of markers for autoimmune disease and cancer.


    Antigen Discovery, Inc.
    Keith B. Hoffman, Ph.D., Head of Business Development
    (949) 679-4068

SOURCE Antigen Discovery, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
4. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
5. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
10. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
11. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):